Severe progressive scarring pembrolizumab‐induced lichen planopilaris in a patient with metastatic melanoma
Australasian Journal of Dermatology2021Vol. 62(3), pp. 403–406
Citations Over Time
Abstract
Lichenoid reactions are one of the many cutaneous immune-related adverse events seen with the use of immune checkpoint inhibitors, particularly anti-PD1 inhibitors. We present a rare care of severe lichen planopilaris secondary to pembrolizumab, with progression even after cessation of immunotherapy. It is important to recognise the significant long-term impact of these cutaneous adverse effects on patient's quality of life.
Related Papers
- → Morphea and lichen sclerosus et atrophicus(1980)115 cited
- → Anogenital Lichen Sclerosus in Women(1996)77 cited
- → Squamous cell carcinoma of the penis arising on lichen sclerosus et atrophicus(1999)15 cited
- → BRITISH MATERNAL AND FETAL MEDICINE SOCIETY SECOND ANNUAL CONFERENCE(1997)2 cited
- [Lichen sclerosus in urological practice].(2006)